Table 2: Association of VEGF-C, VEGFR1 (FLT1), and VEGFR3 (FLT4) mRNA expression with clinicopathological parameters.

VEGF-CVEGFR1 (FLT1)VEGFR3 (FLT4)
LowHigh LowHigh LowHigh

Alcohol consumption.168.324.999
Low4 (20)9 (45)8 (40)5 (25)7 (35)6 (32)
Moderate10 (50)5 (25)5 (25)10 (50)8 (40)7 (37)
High6 (30)6 (30)7 (35)5 (25)5 (25)6 (32)
Site of relapse.009.056.017
Local only17 (85)10 (50)17 (85)10 (50)18 (90)9 (47)
Lymph nodes ± Local3 (19)3 (15)2 (10)4 (20)1 (5)5 (26)
Other0 (0)7 (35)1 (5)6 (30)1 (5)5 (26)
Size at 1st relapse.712.110.999
<2 cm3 (15)4 (20)6 (30)1 (5)4 (20)3 (16)
2–4 cm10 (50)9 (45)11 (55)10 (50)11 (55)9 (47)
>4 cm5 (25)2 (10)2 (10)5 (25)4 (20)3 (16)
Unknown2(10)5 (25)1 (5)4 (20)1 (5)4 (21)
Lymph nodes at diagnosis.342.047.041
N019 (95)16 (80)20 (100)15 (75)20 (100)14 (74)
N1-N21 (5)3 (15)0 (0)4 (20)0 (0)4 (21)
Unknown0 (0)1 (5)0 (0)1 (5)0 (0)1 (5)
Differentiation grade at relapse.697.697.697
Well or moderate14 (70)10 (50)14 (70)10 (50)14 (70)10 (53)
Poor or undifferentiated4 (205 (25)4 (20)5 (25)4 (20)5 (26)
Unknown2 (10)5 (25)2 (10)5 (25)2 (10)4 (21)
Pack years exposure.341.341.751
<52.59 (45)13 (65)9 (45)13 (65)10 (50)11 (58)
>52.511 (55)7 (35)11 (55)7 (35)10 (50)8 (42)
Age.527.999.999
<659 (45)12 (60)11 (55)10 (50)10 (50)10 (53)
>6511 (55)8 (40)9 (45)10 (50)10 (50)9 (47)
Diagnosis to recurrence interval.333.748.748
<12 months6 (30)10 (50)7 (35)9 (45)9 (45)7 (37)
>12 months14 (70)10 (50)13 (65)11 (55)11 (55)12 (63)